Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

ByBrian Drapeau

August 10th 2026

Bristol-Myers Squibb’s new facility is a part of a $40 billion commitment the company pledged to invest in research and development, technology and domestic manufacturing | Image Courtesy of Bristol-Myers Squibb

BMS Bets on Flexible Capacity With $2.3B Texas Campus

ByZachary Zubulake

August 10th 2026

Copenhagen city skyline in Denmark at famous old Nyhavn port | Image Credit: ©f11photo -stock.adobe.com

Danish Biotechs Attracting Investor Attention

ByCheryl Barton

August 10th 2026

PharmTech Weekly Roundup—August 7, 2026

BySusan Haigney

August 7th 2026

From Warehouse to Lakehouse: A Life Sciences Playbook for Regulated, AI-Ready Data Modernization

ByPartha S. Anbil,Deepak Manjarekar

August 7th 2026

April 2003

Articles in this issue

Related Content

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

BMS Bets on Flexible Capacity With $2.3B Texas Campus

Danish Biotechs Attracting Investor Attention

PharmTech Weekly Roundup—August 7, 2026

From Warehouse to Lakehouse: A Life Sciences Playbook for Regulated, AI-Ready Data Modernization

Trending on Pharmaceutical Technology

What Does Moderna's mRNA Flu Vaccine Approval Signal?

Danish Biotechs Attracting Investor Attention

BMS Bets on Flexible Capacity With $2.3B Texas Campus

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Why the Orzeyful Approval Matters Beyond One Drug Class